Will Array-Based Molecular Dx Shops Meet Their Goal of Winning FDA Gold in 2006?

At least seven companies with array-based tests in development speculated over the course of 2005 that 2006 would be the year their respective platforms receive FDA clearance. But now that 06 is upon them, the best many can now offer on the fate of their tests is a cautious maybe. Subscribers: click headline for more

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.